Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients’ Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine

Table 2

Adverse events.

Adverse events	PPV + JTT (𝑛=28)				Total (%)	PPV alone (𝑛=29)				Total (%)
	G1	G2	G3	G4		G1	G2	G3	G4
Injection site reaction	15				15 (54%)	20				20 (69%)
Blood/bone marrow
Leukopenia	3	2			5 (18%)	4				4 (14%)
Lymphopenia	3	2			5 (18%)	3	1			4 (14%)
Anemia	3	4			7 (25%)	2	4			6 (21%)
Thrombocytopenia	1	1			2 (7%)	2		1		3 (10%)
Laboratory
AST increased	2	1			3 (11%)	4	2			6 (21%)
ALT increased	4	1			5 (18%)	3	2			5 (17%)
Bilirubin increased		1			1 (4%)	1				1 (3%)
GGT increased	1	8	1	1	11 (39%)	1	4	3		8 (28%)
ALP increased	2	1	1		4 (14%)	1	2			3 (10%)
Creatinine increased	1				1 (4%)					0 (0%)
Hypoalbuminemia	6	1			7 (25%)	6	2			8 (28%)
Glucose intolerance			1		1 (4%)					0 (0%)
Hyponatremia		1			1 (4%)	2				2 (7%)
Hyperkalemia		1			1 (4%)	1				1 (3%)
Gastrointestinal disorders
Nausea	1				1 (4%)	1	1			2 (7%)
Diarrhea	2				2 (7%)					0 (0%)
Constipation		1			1 (4%)		1			1 (3%)
Abdominal pain	1				1 (4%)	1	2			3 (10%)
Gastroesophageal reflux disease		1			1 (4%)					0 (0%)
Ascites			1		1 (4%)					0 (0%)
Biliary tract infection			1		1 (4%)		1			1 (3%)
Anorexia		3			3 (11%)	1	1	1		3 (10%)
Fever		1			1 (4%)	3				3 (10%)
Pain		2			2 (7%)	2		1		3 (10%)
Edema limbs	1				1 (4%)		2			2 (7%)
Insomnia					0 (0%)		1			1 (3%)
Rash acneiform					0 (0%)	1				1 (3%)